Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Bio | Mind Blowing Facts

What to Expect From Bio-Techne's Q3 2026 Earnings Report

Bio-Techne is set to announce its third-quarter earnings next month, and Wall Street expects the company’s EPS to decrease by a single digit.

Barchart

How Is Bio-Techne's Stock Performance Compared to Other Biotechnology Stocks

Bio-Techne has underperformed other biotechnology stocks over the past year, yet analysts remain moderately optimistic about the stock’s growth potential.

Barchart

How to acquire active contagion sample in Bio-Research and analyze it in Marathon – Selection Pressures 4 Contract guide

The final sample to find.

Destructoid

From analysis to the latest developments in health,
read the most diverse news in one place.

How to synthesize SIMbiont in Quarantine in Marathon – Parasitism 5 guide

The final one.

Destructoid

How to download research clearance in Maintenance and extract Synthsilk Sample in Marathon – Parasitism 4 guide

Get the sample for research.

Destructoid

How to extract Biotic Sample from Sparkleaf in Bio-Research in Marathon – Parasitism 3 contract guide

Inject it!

Destructoid

Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Despite Bio-Techne’s weak performance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

The best probiotics for women, recommended by health experts

‘Clinical trials have proven that supplements that contain live bacteria can help by reducing symptoms of bacterial vaginosis and thrush,’ says Dr Megan Rossi

The Independent UK

Avantor Q2 Feels The Impact From Bioprocessing Shortfalls, Customer Headwinds, Continued Margin Pressure

Avantor Inc. (NYSE:AVTR) stock is trading lower on Friday after the company reported worse-than-expected second-quarter 2025 adjusted EPS.

Benzinga

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) reported better-than-expected second-quarter financial results on Thursday.

Benzinga

The Future of Cancer Treatment Is Here — And It Starts with the Right Clinical Trial

Cancer research no longer moves slowly; it advances rapidly. Revolutionary discoveries in precision medicine, immunotherapy, and gene editing emerge almost weekly, yet many patients still confront enormous hurdles when they look for cutting‑edge options.

International Business Times

Do Wall Street Analysts Like Bio-Techne Stock?

Bio-Techne has notably underperformed the broader market over the past year, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Is Bio-Techne Corporation Stock Underperforming the S&P 500?

Despite Bio-Techne Corporation’s underperformance relative to the S&P 500 over the past year, analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Biotech group warns exit of top FDA vaccine official will ‘erode scientific standards’

Rare admonition from a sector that has largely been silent in the face of the second Trump administration

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Bio-Techne Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Bio-Techne's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's prospects.

Bored Panda

Cryonics Start-Up Extending Life For $200,000 Sparks Hilarious Reactions

"I swear I've seen this movie." The post Cryonics Start-Up Extending Life For $200,000 Sparks Hilarious Reactions first appeared on Bored Panda.

Barchart

Is This Penny Stock a Buy After a 180% Rally?

Bio-Path Holdings surged 180% on promising obesity drug results. Discover why this penny stock's pivot from cancer treatments and Nasdaq delisting challenges could matter for investors.

Barchart

Are Wall Street Analysts Predicting Bio-Techne Stock Will Climb or Sink?

Bio-Techne has underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

I tested the best probiotics recommended by experts to improve gut health

Support your gut health, boost your immune system and reduce bloating with these probiotic supplements

Barchart

Bio-Rad Laboratories Stock: Is BIO Underperforming the Healthcare Sector?

Despite Bio-Rad Laboratories’ underperformance relative to the healthcare sector over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Bio-Techne has underperformed the healthcare sector over the past year, yet analysts remain strongly bullish about the stock’s prospects.

The Independent UK

Congress targets Chinese influence in health tech. It could come with tradeoffs

A San Jose-based biotechnology company that helps doctors detect genetic causes for cancer is among those that could be cut out of the U.S. market over ties to China

Barchart

Is Wall Street Bullish or Bearish on Bio-Techne Stock?

Bio-Techne has underperformed the broader market this year, but Wall Street analysts are optimistic about the stock’s prospects.

International Business Times

How Bio-Safe By BioSecurity Technology Is Setting The New Standard Of Clean

Central to Bio-Safe's strategy is rigorous biofilm control and removal, annihilating the chances of viruses inhabiting it by destroying the protein bonds that protect residing microorganisms.

Barchart

What to Expect From Bio-Techne’s Next Quarterly Earnings Report

With Bio-Techne gearing up to release its fourth-quarter earnings next month, analysts project a double-digit earnings decline.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.